PlumX Metrics
Embed PlumX Metrics

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

Diabetes Care, ISSN: 0149-5992, Vol: 27, Issue: 8, Page: 1915-1921
2004
  • 205
    Citations
  • 0
    Usage
  • 125
    Captures
  • 1
    Mentions
  • 12
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    205
    • Citation Indexes
      202
    • Patent Family Citations
      2
      • Patent Families
        2
    • Policy Citations
      1
      • Policy Citation
        1
  • Captures
    125
  • Mentions
    1
    • News Mentions
      1
      • News
        1
  • Social Media
    12
    • Shares, Likes & Comments
      12
      • Facebook
        12

Most Recent News

Effect of Liraglutide on Fat Mass Percentage Among Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review

Introduction Obesity is a global public health problem. In fact, between 1975 and 2016, the rate of obesity tripled and continuously escalated in pandemic-like proportions.1

Article Description

OBJECTIVE - Glucagon-like peptide (GLP)-1 is a gut hormone that exerts incretin effects and suppresses food intake in humans, but its therapeutic use is limited due to its short half-life. This was a randomized, double-blind, parallel-group, placebo-controlled trial investigating the effect of the long-acting GLP-1 derivative liraglutide (NN2211) on glycemic control, body weight, body composition, and 24-h energy expenditure in obese subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS - Thirty-three patients (mean ± SD) aged 60.0 ± 9.5 years, with HbA 7.5 ± 1.2% and BMI 36.6 ± 4.1 kg/m, were randomized to treatment with a single daily subcutaneous dose of 0.6 mg = 21) of liraglutide (n = 21) or placebo (n = 12) for 8 weeks. In addition to weight and glycemic parameters, body composition was assessed by dual-energy X-ray absorptiometry (DEXA) scanning and 24-h energy expenditure in a respiratory chamber. RESULTS - After 8 weeks, liraglutide reduced fasting serum glucose (liraglutide, -1.90 mmol/l, and placebo, 0.27 mmol/l; P = 0.002) and HbA (liraglutide, -0.33%, and placebo, 0.47%; P = 0.028) compared with placebo. No change in body weight was detected (liraglutide, -0.7 kg, and placebo, -0.9 kg; P = 0.756). There was a nonsignificant trend toward a decrease in total fat mass (liraglutide, -0.98%, and placebo, -0.12%; P = 0.088) and toward an increase in lean body mass (liraglutide, 1.02%, and placebo, 0.23%; P = 0.118) in the liraglutide group compared with the placebo group. Twenty-four-hour energy expenditure was unaffected by the treatment (liraglutide, -12.6 kJ/h, and placebo, -13.7 kJ/h; P = 0.799). CONCLUSIONS - Eight weeks of 0.6-mg liraglutide treatment significantly improved glycemic control without increasing weight in subjects with type 2 diabetes compared with those on placebo. No influence on 24-h energy expenditure was detected.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know